文献速递免疫规划

表达mTRP1或NY-ESO-1的树突状细胞靶向慢病毒载体疫苗联合蛋白疫苗免疫可大幅增强PD1/PDL1阻断对B16黑色素瘤的治疗效果

Therapeutic efficacy of PD1/PDL1 blockade in B16 melanoma is greatly enhanced by immunization with dendritic cell-targeting lentiviral vector and protein vaccine.
PubMed 文献 · Vaccine · 2020-02-20

在B16小鼠黑色素瘤模型中,表达mTRP1或NY-ESO-1的树突状细胞靶向慢病毒载体(ZVex®)作为单药或异源 prime-boost 方案联合重组肿瘤抗原进行免疫。PD1/PDL1阻断显著增强ZVex/mTRP1而非ZVex/NY-ESO-1诱导的免疫应答,抗CTLA4抗体则呈相反效应;ZVex/mTRP1及异源 prime-boost 免疫显著增强抗PD1而非抗PDL1或抗CTLA4的抗肿瘤疗效,提示检查点阻断对自身与非自身肿瘤抗原疫苗诱导的免疫及抗肿瘤应答存在机制差异,可能与耐受及抗肿瘤T细胞耗竭状态有关。

要点

  • PD1/PDL1阻断显著增强ZVex/mTRP1而非ZVex/NY-ESO-1诱导的免疫应答。
  • 抗CTLA4抗体对上述两种疫苗诱导免疫应答的效应与PD1/PDL1阻断相反。
  • ZVex/mTRP1及异源 prime-boost 免疫显著增强抗PD1而非抗PDL1或抗CTLA4的抗肿瘤疗效。

核心结论

  • PD1/PDL1阻断显著增强ZVex/mTRP1而非ZVex/NY-ESO-1诱导的免疫应答,抗CTLA4抗体则呈相反效应。
  • ZVex/mTRP1及异源 prime-boost 免疫显著增强抗PD1而非抗PDL1或抗CTLA4的抗肿瘤疗效。
  • 结果提示检查点阻断对自身与非自身肿瘤抗原疫苗诱导的免疫及抗肿瘤应答存在机制差异,可能与耐受及抗肿瘤T细胞耗竭状态有关。

研究设计与样本

  • 在B16小鼠黑色素瘤模型中,探索表达mTRP1或NY-ESO-1的树突状细胞靶向慢病毒载体(ZVex®)作为单药或异源 prime-boost 方案联合重组肿瘤抗原的免疫方案。

主要发现

  • PD1/PDL1阻断显著增强ZVex/mTRP1而非ZVex/NY-ESO-1诱导的免疫应答。
  • 抗CTLA4抗体对ZVex/mTRP1与ZVex/NY-ESO-1诱导免疫应答的效应与PD1/PDL1阻断相反。
  • ZVex/mTRP1及异源 prime-boost 免疫显著增强抗PD1而非抗PDL1或抗CTLA4的抗肿瘤疗效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

While immune checkpoint inhibition is rapidly becoming standard of care in many solid tumors, immune checkpoint inhibitors (ICIs) fail to induce clinical responses in many patients, presumably due to insufficient numbers of tumor-specific T cells in the tumor milieu. To this end, immunization protocols using viral vectors expressing tumor-associated antigens are being explored to induce T cell responses that synergize with ICIs. However, the optimal combination of vaccine and immune checkpoint regimen remains undefined. Here, a dendritic cell-targeting lentiviral vector (ZVex®) expressing the endogenous murine tyrosinase-related protein 1 (mTRP1), or the human tumor antigen NY-ESO-1, was explored as monotherapy or heterologous prime-boost (HPB) vaccine regimen together with recombinant tumor antigen in the murine B16 melanoma model. PD1/PDL1 blockade significantly enhanced ZVex/mTRP1, but not ZVex/NY-ESO-1, induced immune responses in mice, whereas the opposite effect was observed with anti-CTLA4 antibody. Anti-tumor efficacy of anti-PD1, but not anti-PDL1 or anti-CTLA4, was significantly enhanced by ZVex/mTRP1 and HPB vaccination. These results suggest mechanistic differences in the effect of checkpoint blockade on vaccine-induced immune and anti-tumor responses against self versus non-self tumor antigens, possibly due to tolerance and state of exhaustion of anti-tumor T cells.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Albershardt TC, Parsons AJ, Reeves RS, et al. Therapeutic efficacy of PD1/PDL1 blockade in B16 melanoma is greatly enhanced by immunization with dendritic cell-targeting lentiviral vector and protein vaccine. Vaccine. 2020. PMID: 32088020. doi:10.1016/j.vaccine.2020.02.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。